microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells

Mao,Yeqing; Chen,Hong; Lin,Yiwei; Xu,Xin; Hu,Zhenghui; Zhu,Yi; Wu,Jian; Xu,Xianglai; Zheng,Xiangyi; Xie,Liping

doi:10.3892/or.2013.2452

microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells

Authors:
- Yeqing Mao
- Hong Chen
- Yiwei Lin
- Xin Xu
- Zhenghui Hu
- Yi Zhu
- Jian Wu
- Xianglai Xu
- Xiangyi Zheng
- Liping Xie
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: May 13, 2013 https://doi.org/10.3892/or.2013.2452
Pages: 327-333

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs), small non-coding RNAs, have emerged as key regulators of a large number of genes. The present study aimed to explore novel biological functions of miR-330 in the human prostate cancer cell lines DU145 and PC3. We confirmed that miR-330 was downregulated and inversely correlated with specificity protein 1 (Sp1) expression. Overexpression of miR-330 by transfection of a chemically synthesized miR-330 mimic induced a reduction in expression levels of the Sp1 protein, accompanied by significant suppression of cellular migration and invasion capability. In addition, the Sp1-knockdown experiments presented similar phenomena. Finally, the luciferase reporter assay validated Sp1 as the direct target of miR-330. These findings indicate that miR-330 acts as an anti-metastatic miRNA in prostate cancer.

View References

1	Ambros V and Chen X: The regulation of genes and genomes by small RNAs. Development. 134:1635–1641. 2007. View Article : Google Scholar : PubMed/NCBI
2	Hutvágner G and Zamore PD: A microRNA in a multiple-turnover RNAi enzyme complex. Science. 297:2056–2060. 2002.PubMed/NCBI
3	Hwang HW and Mendell JT: microRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96(Suppl): R40–R44. 2007.PubMed/NCBI
4	Ryan BM, Robles AI and Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kasinski AL and Slack FJ: Epigenetics and genetics. microRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
6	Weber MJ: New human and mouse microRNA genes found by homology search. FEBS J. 272:59–73. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gaur A, Jewell DA, Liang Y, et al: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67:2456–2468. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ruike Y, Ichimura A, Tsuchiya S, et al: Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines. J Hum Genet. 53:515–523. 2008. View Article : Google Scholar : PubMed/NCBI
9	Neville PJ, Conti DV, Krumroy LM, et al: Prostate cancer aggressiveness locus on chromosome segment 19q12-q13. 1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer. 36:332–339. 2003. View Article : Google Scholar : PubMed/NCBI
10	Slager SL, Schaid DJ, Cunningham JM, et al: Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet. 72:759–762. 2003. View Article : Google Scholar : PubMed/NCBI
11	Qu S, Yao Y, Shang C, et al: microRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLoS One. 7:e460102012. View Article : Google Scholar : PubMed/NCBI
12	Lee KH, Chen YL, Yeh SD, et al: microRNA-330 acts as tumorsuppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene. 28:3360–3370. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chintharlapalli S, Papineni S, Ramaiah SK and Safe S: Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 67:2816–2823. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sankpal UT, Goodison S, Abdelrahim M and Basha R: Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
15	Pore N, Liu S, Shu HK, et al: Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell. 15:4841–4853. 2004. View Article : Google Scholar : PubMed/NCBI
16	Baranwal S and Alahari SK: miRNA control of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290. 2010.PubMed/NCBI
17	Iorio MV and Croce CM: microRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
18	Watahiki A, Wang Y, Morris J, et al: microRNAs associated with metastatic prostate cancer. PLoS One. 6:e249502011. View Article : Google Scholar : PubMed/NCBI
19	Chiefari E, Brunetti A, Arturi F, et al: Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer. 2:352002. View Article : Google Scholar : PubMed/NCBI
20	Shi Q, Le X, Abbruzzese JL, et al: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:4143–4154. 2001.
21	Yao JC, Wang L, Wei D, et al: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 10:4109–4117. 2004. View Article : Google Scholar
22	Zannetti A, Del Vecchio S, Carriero MV, et al: Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res. 60:1546–1551. 2000.PubMed/NCBI
23	Chen JL, Attardi LD, Verrijzer CP, Yokomori K and Tjian R: Assembly of recombinant TFIID reveals differential coactivator requirements for distinct transcriptional activators. Cell. 79:93–105. 1994. View Article : Google Scholar : PubMed/NCBI
24	Furukawa T and Tanese N: Assembly of partial TFIID complexes in mammalian cells reveals distinct activities associated with individual TATA box-binding protein-associated factors. J Biol Chem. 275:29847–29856. 2000. View Article : Google Scholar
25	Majello B, Napolitano G, De Luca P and Lania L: Recruitment of human TBP selectively activates RNA polymerase II TATA-dependent promoters. J Biol Chem. 273:16509–16516. 1998. View Article : Google Scholar : PubMed/NCBI
26	Sadovsky Y, Webb P, Lopez G, et al: Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol Cell Biol. 15:1554–1563. 1995.PubMed/NCBI
27	Murthy S, Ryan AJ and Carter AB: SP-1 regulation of MMP-9 expression requires Ser586 in the PEST domain. Biochem J. 445:229–236. 2012.PubMed/NCBI
28	Qin H, Sun Y and Benveniste EN: The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem. 274:29130–29137. 1999. View Article : Google Scholar : PubMed/NCBI
29	Wang CH, Chang HC and Hung WC: p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J Cell Physiol. 208:246–252. 2006. View Article : Google Scholar : PubMed/NCBI